Applicable to both IDP and refugee scenarios, the Toolkit incorporates a wide range of relevant information on managing displaced populations living in communal settings (collective centres, spontaneous sites, established camps, etc.). Large scale displacements caused by recent conflict and natural ...disaster events have created a high demand for the Toolkit, which has proven an invaluable resource for field practitioners, government actors and displaced populations since its original release in 2004.
Available in other languages
more
March 2020
This document provides a high-level mapping of outbreak stages with guidance on how to time the minimum uptake of different interventions that have been recommended by Africa CDC, driven by evidence and science.
One Earth Perspective. Cell Press
IBOGA Review No.1 Revue Scientifique du Jésuites d'Afrique de l'Ouest
SAHARA-J: Journal
of Social Aspects of HIV/AIDS, 13:1, 1-7, DOI: 10.1080/17290376.2015.1123646
-Covid-19 и беременность
-Особенности применения методов диагностики у беременных
-Особенности лечения covid-19 при беременности
-Акушерская тактика при covid-19
-Маршрути...ация беременных и их новорожденных
-Организация работы родовспомогательных учреждений в период пандемии covid-19
medical care for pregnant women, women in labour, newborns and newborns in case a COVID-19 coronavirus infection
more
Heart failure with a reduced ejection fraction (HFrEF) is a condition frequently encountered by healthcare professionals and, in order to achieve the best outcomes for patients, needs to be managed optimally. This guideline document is based on the European Society of Cardiology Guidelines for the t...reatment of acute and chronic heart failure published in 2016, and summarises what is considered the best current management of patients with the condition. It provides information on the definition, diagnosis and epidemiology of HFrEF in the African context. The best evidence-based treatments for HFrEF are discussed, including established therapies (beta-blockers, ACE-i/ARBs, mineralocorticoid receptor antagonists (MRAs), diuretics) that form the cornerstone of heart failure management as well as therapies that have only recently entered clinical use (angiotensin receptor-neprilysin inhibitor (ARNI), sodium/glucose cotransporter-2 (SGLT2) inhibitors). Guidance is offered in terms of more invasive therapies (revascularisation, implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy (CRT) by implantation of a biventricular pacemaker with (CRT-D) or without (CRT-P) an ICD, left ventricular assist device (LVAD) use and heart transplantation) in order to ensure efficient use of these expensive treatment modalities in a resourcelimited environment. Furthermore, additional therapies (digoxin, hydralazine and nitrates, ivabradine, iron supplementation) are discussed and advice is provided on general preventive strategies (vaccinations). Sections to discuss conditions that are particularly prevalent in sub-Saharan Africa (HIV-associated cardiomyopathy (CMO), peripartum CMO, rheumatic heart disease, atrial fibrillation) have been added to further improve clinical care for these commonly encountered disease processes.
more
Research
BMJ 2014;349:g4643 doi: 10.1136/bmj.g4643 (Published 5 August 2014), 1-11
The document provides detailed clinical guidelines for the therapy of Type 1 Diabetes as developed by the German Diabetes Association (DDG). It focuses on individualized insulin therapy, structured patient training, and monitoring of blood glucose levels. The guidelines emphasize preventing complica...tions like ketoacidosis and hypoglycemia while improving patients' quality of life through education and tailored medical care. Recommendations include the use of both basal and bolus insulin, continuous glucose monitoring, and integrating psychosocial support into treatment plans. The document serves as a comprehensive resource for healthcare professionals managing Type 1 Diabetes.
more
Bisher hat die STIKO empfohlen, dass alle im Ausland mit einem nicht in der EU zugelassenen Impfstoff geimpften Personen eine erneute Impfserie mit einem in der EU zugelassenen Impfstoff erhalten sollen. Ziel der im Epidemiologischen Bulletin 13/2022 veröffentlichten aktualisierten COVID-19-Impfemp...fehlung ist es, Personen, die eine COVID-19-Impfung mit einem der nicht in der EU zugelassenen Ganzvirusimpfstoffen (CoronaVac, Covilo und Covaxin) oder dem Vektor-basierten Impfstoff Sputnik V erhalten haben, mit einem Impfschutz auszustatten, der vergleichbar mit dem einer Grundimmunisierung plus Auffrischimpfung mit einem mRNA-Impfstoff ist.
more
PLOS ONE | https://doi.org/10.1371/journal.pone.0196239 April 23, 2018
Patients with diabetes are at increased risk of developing cardiovascular disease (CVD) with its manifestations of coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), and stroke, as well as aortic and peripheral artery diseases. In addition, diabetes is a major risk factor f...or developing chronic kidney disease (CKD), which in itself is associated with developing CVD. The combination of diabetes with these cardio-renal comorbidities enhances the risk not only for cardiovascular (CV) events but also for CV and all-cause mortality. The current European Society of Cardiology (ESC) Guidelines on the management of cardiovascular disease in patients with diabetes are designed to guide prevention and management of the manifestations of CVD in patients with diabetes based on data published until end of January 2023. Over the last decade, the results of various large cardiovascular outcome trials (CVOTs) in patients with diabetes at high CV risk with novel glucose- lowering agents, such as sodium–glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), but also novel non-steroidal mineralocorticoid receptor antagonists (MRAs), such as finerenone have substantially expanded available therapeutic op-
tions, leading to numerous evidence-based recommendations for the management of this patient population.
more
Journal of Social Aspects of HIV/AIDS VOL. 13 NO. 1 2016
To link to this article: https://doi.org/10.1080/17290376.2016.1226942
Guías de promoción de la salud y prevención de enfermedades en la salud pública no.23
PLoS ONE 9(6): e99880. doi:10.1371/journal.pone.0099880
Published June 17, 2014
Informe sobre poblaciones clave.
Indian J Psychiatry. 2017 Jan; 59(Suppl 1): S67–S73.
doi: 10.4103/0019-5545.196975: 10.4103/0019-5545.196975